Category: news

Aaron speaks at the University of Colorado Cancer Center. Thank you to Dr. Sabrina Spencer for hosting. A great opportunity to make new friends and reconnect with former colleagues and trainees!

Check out a new manuscript “Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction” now posted to bioRxiv! This is the product of a terrific collaboration with the Weiskopf lab at MIT.

Aaron has been elected to the American Society for Clinical Investigation (ASCI)!

We say farewell to Danielle who will be attending a Software Bootcamp at General Assembly. Best wishes to you in your future endeavors – we will miss you!

We are excited to report the results of this collaboration with Nuvalent at the 2022 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics: NVL-655 shows activity against lorlatinib-resistant ALK NSCLC experimental models harboring compound ALK resistance mutations.

Chendi’s manuscript on the MCL-1 dependency of KRAS-LKB1 mutant NSCLC is now posted to bioRxiv! This describes a novel mechanism by which LKB1 regulates apoptotic signaling via NUAK1/2 and JNK.

We say farewell to Justine who has joined Accretio Management as a Life Sciences Associate. Best wishes to you in your future endeavors – we will miss you!

We say farewell to Adam who will be getting his masters in Medical Sciences at Boston University school of medicine. Best wishes to you in your future endeavors – we will miss you!

Welcome to Anahita Nimbalkar who joins our group as a research technician. 

Welcome to Grace Kelley who joins our group as a research technician on the model development team.